Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 13, 2010

IVAX Inks Distribution Deal for Biomerica’s ELISA Kits and POC Tests

  • IVAX Diagnostics entered a two-year agreement with Biomerica for the global distribution of the latter’s products, with certain country and product exclusions. Products covered under the deal include 33 ELISA test kits in the areas of diabetes, gastrointestinal disease, and bone/mineral disorders as well as more than 26 point-of-care tests.

    IVAX’ subsidiaries Diamedix and Delta Biologicals will supply the products, which will be marketed under the Biomerica name. If certain initial sales levels are achieved, the products will be sold under the Diamedix brand in the U.S. and the Delta Biologicals brand internationally.

    “This agreement with Biomerica is expected to not only broaden and enhance our ELISA suite of products by adding GI, diabetes, and bone/mineral testing products to our line of autoimmune test kits but also expand our entry into the rapid point-of-care testing market, a global market that is estimated to be $10.3 billion,” comments Charles Struby, CEO and president of IVAX.

    Zackary Irani, CEO of Biomerica, adds, “IVAX Diagnostics’ customer base of nearly 600 installed Mago® instruments [an analyzer for ELISA procedures] offers both our companies a significant opportunity to increase sales. As our tests complement those already sold by Diamedix and Delta Biologicals, we believe their experienced sales forces and ability to reach global markets will produce positive results.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »